200 related articles for article (PubMed ID: 16936711)
1. Risperidone and paliperidone inhibit p-glycoprotein activity in vitro.
Zhu HJ; Wang JS; Markowitz JS; Donovan JL; Gibson BB; DeVane CL
Neuropsychopharmacology; 2007 Apr; 32(4):757-64. PubMed ID: 16936711
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein.
Wang JS; Zhu HJ; Markowitz JS; Donovan JL; DeVane CL
Psychopharmacology (Berl); 2006 Sep; 187(4):415-23. PubMed ID: 16810505
[TBL] [Abstract][Full Text] [Related]
3. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana.
Zhu HJ; Wang JS; Markowitz JS; Donovan JL; Gibson BB; Gefroh HA; Devane CL
J Pharmacol Exp Ther; 2006 May; 317(2):850-7. PubMed ID: 16439618
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein-mediated efflux of phenobarbital at the blood-brain barrier evidence from transport experiments in vitro.
Yang ZH; Liu XD
Epilepsy Res; 2008 Jan; 78(1):40-9. PubMed ID: 18063342
[TBL] [Abstract][Full Text] [Related]
5. Stereoselective Regulation of P-gp Activity by Clausenamide Enantiomers in Caco-2, KB/KBv and Brain Microvessel Endothelial Cells.
Zhu CJ; Hua F; Zhu XL; Li M; Wang HX; Yu XM; Li Y
PLoS One; 2015; 10(8):e0135866. PubMed ID: 26295572
[TBL] [Abstract][Full Text] [Related]
6. Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein.
Inoue T; Osada K; Tagawa M; Ogawa Y; Haga T; Sogame Y; Hashizume T; Watanabe T; Taguchi A; Katsumata T; Yabuki M; Yamaguchi N
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct; 39(1):156-62. PubMed ID: 22691713
[TBL] [Abstract][Full Text] [Related]
7. Expression and functional activity of P-glycoprotein in passaged primary human nasal epithelial cell monolayers cultured by the air-liquid interface method for nasal drug transport study.
Cho HJ; Choi MK; Lin H; Kim JS; Chung SJ; Shim CK; Kim DD
J Pharm Pharmacol; 2011 Mar; 63(3):385-91. PubMed ID: 21749386
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of P-glycoprotein function by procyanidine on blood-brain barrier.
He L; Zhao C; Yan M; Zhang LY; Xia YZ
Phytother Res; 2009 Jul; 23(7):933-7. PubMed ID: 19172664
[TBL] [Abstract][Full Text] [Related]
9. The possible clinical impact of risperidone on P-glycoprotein-mediated transport of tacrolimus: A case report and in vitro study.
Watanabe N; Higashi H; Nakamura S; Nomura K; Adachi Y; Taguchi M
Biopharm Drug Dispos; 2018 Jan; 39(1):30-37. PubMed ID: 29055041
[TBL] [Abstract][Full Text] [Related]
10. Interaction of imatinib mesilate with human P-glycoprotein.
Hamada A; Miyano H; Watanabe H; Saito H
J Pharmacol Exp Ther; 2003 Nov; 307(2):824-8. PubMed ID: 12975485
[TBL] [Abstract][Full Text] [Related]
11. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells.
Sachs-Barrable K; Thamboo A; Lee SD; Wasan KM
J Pharm Pharm Sci; 2007; 10(3):319-31. PubMed ID: 17727795
[TBL] [Abstract][Full Text] [Related]
12. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro.
Perloff ES; Duan SX; Skolnik PR; Greenblatt DJ; von Moltke LL
Drug Metab Dispos; 2005 Jun; 33(6):764-70. PubMed ID: 15764714
[TBL] [Abstract][Full Text] [Related]
13. Effects of various principles from Chinese herbal medicine on rhodamine123 accumulation in brain capillary endothelial cells.
He L; Liu GQ
Acta Pharmacol Sin; 2002 Jul; 23(7):591-6. PubMed ID: 12100750
[TBL] [Abstract][Full Text] [Related]
14. Methadone inhibits rhodamine123 transport in Caco-2 cells.
Störmer E; Perloff MD; von Moltke LL; Greenblatt DJ
Drug Metab Dispos; 2001 Jul; 29(7):954-6. PubMed ID: 11408360
[TBL] [Abstract][Full Text] [Related]
15. Real-time analysis of P-glycoprotein-mediated drug transport across primary intestinal epithelium three-dimensionally cultured in vitro.
Mizutani T; Nakamura T; Morikawa R; Fukuda M; Mochizuki W; Yamauchi Y; Nozaki K; Yui S; Nemoto Y; Nagaishi T; Okamoto R; Tsuchiya K; Watanabe M
Biochem Biophys Res Commun; 2012 Mar; 419(2):238-43. PubMed ID: 22342245
[TBL] [Abstract][Full Text] [Related]
16. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines.
van der Sandt IC; Blom-Roosemalen MC; de Boer AG; Breimer DD
Eur J Pharm Sci; 2000 Sep; 11(3):207-14. PubMed ID: 11042226
[TBL] [Abstract][Full Text] [Related]
17. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats.
Sugimoto H; Hirabayashi H; Kimura Y; Furuta A; Amano N; Moriwaki T
Drug Metab Dispos; 2011 Jan; 39(1):8-14. PubMed ID: 20962062
[TBL] [Abstract][Full Text] [Related]
18. Effects of P-glycoprotein inhibitors on transepithelial transport of cadmium in cultured renal epithelial cells, LLC-PK1 and LLC-GA5-COL 150.
Kimura O; Endo T; Hotta Y; Sakata M
Toxicology; 2005 Mar; 208(1):123-32. PubMed ID: 15664439
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments.
Ejsing TB; Pedersen AD; Linnet K
Hum Psychopharmacol; 2005 Oct; 20(7):493-500. PubMed ID: 16118767
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of P-glycoprotein-mediated transport by terpenoids contained in herbal medicines and natural products.
Yoshida N; Koizumi M; Adachi I; Kawakami J
Food Chem Toxicol; 2006 Dec; 44(12):2033-9. PubMed ID: 16904803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
